ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年02月22日 14時00分
Source:
Eisai
エーザイ、新規線維芽細胞増殖因子（FGF）受容体選択的チロシンキナーゼ阻害剤E7090が日本においてFGFR2融合遺伝子を有する切除不能な胆道がんを予定される効能・効果として厚生労働省より希少疾病用医薬品に指定
東京, 2021年02月22日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社が創製し、経口投与可能な新規抗がん剤として開発中の線維芽細胞増殖因子（FGF）受容体（FGFR1、FGFR2、FGFR3）選択的チロシンキナーゼ阻害剤E7090について、FGFR2融合遺伝子を有する切除不能な胆道がんを予定される効能・効果として、厚生労働省より希少疾病用医薬品（オーファンドラッグ）に指定されたことをお知らせします。
FGFRの遺伝子異常はがん細胞の増殖、生存、遊走、腫瘍血管新生、薬剤耐性などに重要な役割を果たしていることが知られています。また、様々ながん腫においてFGFRの遺伝子異常が認められていることから、がん治療の有望な標的として注目されています。E7090は、FGFR1、2、3を選択的に阻害し、そのシグナルを遮断することにより、FGFRの遺伝子異常を有するがんに対する新たな分子標的治療薬となる可能性があります。
E7090は、日本において臨床第Ⅰ相試験を実施し、FGFR2融合遺伝子を有する切除不能な胆道がんに対する治療を対象に、厚生労働省の「先駆け審査指定制度」の対象品目に指定されています。現在、日本、中国においてFGFR2融合遺伝子を有する胆管がん患者様を対象とした臨床第II相試験（201試験）が進行中です。
当社は、がん領域を重点領域の一つと位置づけており、がんの「治癒」に向けた画期的な新薬創出をめざしています。E7090によるがん治療の可能性を引き続き追求し、がん患者様とそのご家族の多様なニーズの充足とベネフィット向上により一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2021/news202108.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 03:24 JST
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 03:06 JST
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 02:42 JST
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 02:06 JST
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.
Dec 18, 2025 22:00 JST
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
Dec 15, 2025 23:00 JST
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 08:30 JST
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
Honda to Launch New Heritage Service Business
Dec 12, 2025 20:31 JST
Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz
Dec 12, 2025 19:59 JST
NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries
Dec 12, 2025 18:13 JST
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 11, 2025 19:41 JST
NEC Named to CDP's "A List" for Climate Change and Water Security for the Seventh Consecutive Year
Dec 11, 2025 19:00 JST
MHI Successfully Produces Hydrogen at Its Ammonia Cracking Pilot Plant Using Steam Heating
Dec 10, 2025 18:14 JST
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Dec 10, 2025 12:00 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 09, 2025 18:51 JST
NEC Wins TIP MUST Silver Badge with Advanced Network Operating System for Open Optical Transponders
Dec 09, 2025 13:39 JST
More Latest Release >>
Related Release
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/26/2025 7:42:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
11/17/2025 10:08:00 PM JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
10/30/2025 2:43:00 PM JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
10/29/2025 12:30:00 AM JST
More Press release >>